Skip to main content
NVDA+0.46%AAPL+0.18%GOOGL+0.93%MSFT+0.18%AMZN+0.10%TSM-0.16%SPCX+1.09%META+0.16%AVGO-1.10%TSLA-0.07%SKHY-1.36%MU+0.02%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%ABBV-0.65%1398.HK+0.78%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%PM-1.59%1288.HK+0.61%MS-2.43%GBPAUD+1.24%AUDUSD-1.12%AUDJPY-1.07%GBPCHF+0.99%USDCHF+0.85%GBPCAD+0.77%CHFJPY-0.73%GBPNZD+0.66%USDCAD+0.65%EURGBP-0.65%EURAUD+0.61%AUDNZD-0.57%CADJPY-0.57%NZDUSD-0.55%USDTHB+0.55%EURUSD-0.54%AUDCAD-0.50%EURJPY-0.46%NZDJPY-0.46%GBPTRY+0.41%GBPHKD+0.32%EURCHF+0.31%NZDCHF+0.31%AUDCHF-0.30%USDTRY+0.29%GBPMXN-0.28%USDCNH-0.20%CADCHF+0.20%GBPJPY+0.20%USDILS+0.16%GBPUSD+0.12%EURCAD+0.12%NZDCAD+0.10%USDMXN+0.10%USDJPY+0.07%USDZAR+0.06%NZDMXN+0.06%USDCOP-0.04%GBPZAR+0.04%GBPSGD-0.03%USDHKD+0.03%AUDNOK+0.03%NZDSGD-0.03%EURNZD+0.03%EURHKD-0.01%USDSGD-0.01%EURCNH-0.01%EURSGD-0.01%USDDKK-0.01%CHFSGD+0.01%EURDKK0.00%AUDDKK0.00%AUDSGD0.00%SGDJPY0.00%EURSEK0.00%PLNJPY0.00%USDNOK0.00%NOKJPY0.00%EURCZK0.00%EURNOK0.00%USDSEK0.00%USDPLN0.00%CHFNOK0.00%EURZAR0.00%CHFSEK0.00%EURPLN0.00%XPTUSD-0.45%XNGUSD+0.37%USOIL-0.27%HG1-0.22%GAGUSD-0.14%XAGUSD-0.14%GAUUSD-0.11%XAUUSD-0.11%W10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.03%ETHUSD+7.44%USDTUSD-0.01%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.98%ZECUSDT+1.55%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.13%XLMUSD+2.55%BCHUSDT-0.38%UNIUSD+0.19%LTCUSD+0.07%HBARUSDT+2.84%SUIUSD+1.20%TONUSD+15.77%TAOUSDT+0.58%AAVEUSD-3.31%DOTUSDT+2.78%ICPUSDT-3.21%ONDOUSDT-0.15%WLDUSDT+10.30%ARBUSDT-0.24%JUPUSDT+0.10%ATOMUSDT+0.93%INJUSDT-2.78%STXUSDT+17.54%FETUSDT+1.45%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.18%OPUSDT+0.54%WIFUSDT+3.87%IOTAUSDT+4.42%POLUSDT-3.13%AXSUSDT+0.59%FARTCOINUSDT-0.26%EOSUSDT+4.07%DYDXUSDT+3.84%GALAUSDT+5.20%ORDIUSDT+0.99%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.46%AAPL+0.18%GOOGL+0.93%MSFT+0.18%AMZN+0.10%TSM-0.16%SPCX+1.09%META+0.16%AVGO-1.10%TSLA-0.07%SKHY-1.36%MU+0.02%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%ABBV-0.65%1398.HK+0.78%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%PM-1.59%1288.HK+0.61%MS-2.43%GBPAUD+1.24%AUDUSD-1.12%AUDJPY-1.07%GBPCHF+0.99%USDCHF+0.85%GBPCAD+0.77%CHFJPY-0.73%GBPNZD+0.66%USDCAD+0.65%EURGBP-0.65%EURAUD+0.61%AUDNZD-0.57%CADJPY-0.57%NZDUSD-0.55%USDTHB+0.55%EURUSD-0.54%AUDCAD-0.50%EURJPY-0.46%NZDJPY-0.46%GBPTRY+0.41%GBPHKD+0.32%EURCHF+0.31%NZDCHF+0.31%AUDCHF-0.30%USDTRY+0.29%GBPMXN-0.28%USDCNH-0.20%CADCHF+0.20%GBPJPY+0.20%USDILS+0.16%GBPUSD+0.12%EURCAD+0.12%NZDCAD+0.10%USDMXN+0.10%USDJPY+0.07%USDZAR+0.06%NZDMXN+0.06%USDCOP-0.04%GBPZAR+0.04%GBPSGD-0.03%USDHKD+0.03%AUDNOK+0.03%NZDSGD-0.03%EURNZD+0.03%EURHKD-0.01%USDSGD-0.01%EURCNH-0.01%EURSGD-0.01%USDDKK-0.01%CHFSGD+0.01%EURDKK0.00%AUDDKK0.00%AUDSGD0.00%SGDJPY0.00%EURSEK0.00%PLNJPY0.00%USDNOK0.00%NOKJPY0.00%EURCZK0.00%EURNOK0.00%USDSEK0.00%USDPLN0.00%CHFNOK0.00%EURZAR0.00%CHFSEK0.00%EURPLN0.00%XPTUSD-0.45%XNGUSD+0.37%USOIL-0.27%HG1-0.22%GAGUSD-0.14%XAGUSD-0.14%GAUUSD-0.11%XAUUSD-0.11%W10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.03%ETHUSD+7.44%USDTUSD-0.01%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+0.98%ZECUSDT+1.55%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.13%XLMUSD+2.55%BCHUSDT-0.38%UNIUSD+0.19%LTCUSD+0.07%HBARUSDT+2.84%SUIUSD+1.20%TONUSD+15.77%TAOUSDT+0.58%AAVEUSD-3.31%DOTUSDT+2.78%ICPUSDT-3.21%ONDOUSDT-0.15%WLDUSDT+10.30%ARBUSDT-0.24%JUPUSDT+0.10%ATOMUSDT+0.93%INJUSDT-2.78%STXUSDT+17.54%FETUSDT+1.45%SEIUSDT+0.33%PYTHUSDT-2.32%TIAUSDT+0.16%IMXUSDT+0.97%GRTUSDT-0.18%OPUSDT+0.54%WIFUSDT+3.87%IOTAUSDT+4.42%POLUSDT-3.13%AXSUSDT+0.59%FARTCOINUSDT-0.26%EOSUSDT+4.07%DYDXUSDT+3.84%GALAUSDT+5.20%ORDIUSDT+0.99%NOTUSDT+1.55%RONINUSDT+0.06%
RP

Royalty Pharma plc (RPRX)

NASDAQ • Healthcare

$58.36
+$0.14 (+0.2%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$58.21
Day Range$57.7 - $58.64
Avg. Volume (3M)3.2M
Market Cap$25.8B
P/E Ratio24.2
52 Week Range
$35.23$64.38
Next EarningsIn 35 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$674.1M100%
Gross Profitminus cost of goods$405.9M60%
Operating Incomeminus R&D and overhead$133M20%
Net Incomeminus taxes and the rest$17.8M3%

In plain terms: out of every $100 in revenue, Royalty Pharma plc keeps $3 as net profit.

Fundamentals & Financials

Revenue (TTM)
$2.5B
Net Income (TTM)
$815.3M
EPS (TTM)
$2.41
ROA (TTM)
4.11%
Current Ratio
1.29
Dividend Yield
0.42%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+13.2%Q1 2026$1.46
+7.4%Q2 2026$1.3
+3.9%Q3 2026$1.32
Next

Nov 4

in 35 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +3.9%

Royalty Pharma plc beat consensus on adjusted EPS in the second fiscal quarter of 2026, reported Aug. 5, with adjusted EPS of $1.32 topping the $1.27 estimate by 3.9% and rising 15.8% from $1.14 a year ago. Revenue rose 16.5% to about $674.1 million from $578.7 million a year earlier, while gross profit came in at about $405.9 million and gross margin held near 60%; operating income was about $133.0 million, with operating margin near 20%. The company generated operating cash flow of about $728.0 million and paid $105.0 million in dividends. Consensus for the next period calls for EPS of $1.12.

View full earnings history

About Royalty Pharma plc

Royalty Pharma plc (NASDAQ: RPRX) operates in healthcare as a buyer of biopharmaceutical royalties and a funder of drug innovation, centered on the United States. The company records revenue from royalty interests tied to approved and pipeline medicines, and generated $2.4 billion in FY2025.

Name
Royalty Pharma plc
CEO
Pablo Legorreta
Website
www.royaltypharma.com
Industry
Healthcare
Year Founded
1996
Employees
100

Today's Snapshot

AI-generated

RPRX ended the day slightly higher at 58.36, while its sector was weaker.

Trading Volume

Above 10d avg 3.0M

3.6M

vs S&P 500 Today

Inline with Market

+0.05%

Updated: September 30, 2026 at 20:21 UTC

RPRX Headlines

Novartis pelacarsen trial misses key endpoint

September 5, 2026

3 min read
View All News

Technical Indicators

2 Buy2 Neutral4 Sell
RPRX presents a mixed but unfavorable picture: trend strength is elevated enough to suggest directionality, and MACD is negative, while RSI and other oscillators remain neutral, indicating limited bullish momentum. The stock is trading around short-term averages and comfortably above the 200-day, showing longer-term support even as medium-term moving averages sit higher; ATR indicates moderate intraday range. OBV shows net outflows, which tempers the bullish long-term view and aligns with the slightly negative momentum. Technical takeaway: Sell — medium-term pressure outweighs longer-term support.
All signals
  • EMA (5 indicators)$51.04 - $58.99
    Sell
  • RSI (14)44.03
    Neutral
  • Stochastic %K (14, 3, 3)29.07
    Neutral
  • MACD Level (12, 26)-0.51
    Sell

Peers & Related Assets

ROIVRoivant Sciences Ltd.
$36.57+0.2%
INCYIncyte Corporation
$121.35-1.5%
UTHRUnited Therapeutics Corporation
$541.89+12.6%
THCTenet Healthcare Corporation
$255.56-0.8%
EXELExelixis, Inc.
$58.41-0.4%
SMMTSummit Therapeutics Inc.
$16.91+3.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.